SA519410841B1 - تركيبة مستحلب نانو زيت في ماء من كلوبيتاسول - Google Patents

تركيبة مستحلب نانو زيت في ماء من كلوبيتاسول

Info

Publication number
SA519410841B1
SA519410841B1 SA519410841A SA519410841A SA519410841B1 SA 519410841 B1 SA519410841 B1 SA 519410841B1 SA 519410841 A SA519410841 A SA 519410841A SA 519410841 A SA519410841 A SA 519410841A SA 519410841 B1 SA519410841 B1 SA 519410841B1
Authority
SA
Saudi Arabia
Prior art keywords
oil
comprised
clobetasol
weight ratio
nanoemulsion
Prior art date
Application number
SA519410841A
Other languages
English (en)
Inventor
جانان ماريا اسابيل ديلجادو
اكويلو جافير ساناجوستين
جريس ماريا ديل كارمين ليندينز
Original Assignee
لابوراتوريس سالفات اس.ايه
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by لابوراتوريس سالفات اس.ايه filed Critical لابوراتوريس سالفات اس.ايه
Publication of SA519410841B1 publication Critical patent/SA519410841B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Colloid Chemistry (AREA)
  • Cosmetics (AREA)

Abstract

يتعلق الاختراع الحالي بتركيبة مستحلب نانو زيت oil-in-water nanoemulsion composition في ماء لها طور مائي مستمر continuous aqueous phase وقطيرات زيت مشتتة dispersed oil droplets، حيث يشتمل المستحلب النانو على: (أ) كلوبيتاسول clobetasol؛ واحد أو أكثر من مكونات الزيت oil components؛ و(ج) واحد أو أكثر من منشطات السطح surfactants؛ بجانب واحد أو أكثر من السواغات excipients أو المواد الحاملة carriers المقبولة صيدلانياً حيث: تتكون أسمولية تركيبة المستحلب النانو من 100 إلى 500 مللي أسمول/ كجم؛ يتكون متوسط حجم قطيرة مقاس بواسطة تشتت الضوء الديناميكي Dynamic light scattering من 1 نانومتر إلى 500 نانومتر؛ تتكون نسبة الوزن بين مكونات الزيت ومجموع مكونات الزيت وواحد أو أكثر من منشطات السطح من 0.001 إلى 0.5؛ تتكون نسبة الوزن بين مكون الزيت والكلوبيتاسول من 1: 1 إلى 200: 1؛ وتتكون نسبة الوزن بين منشط السطح surfactant والكلوبيتاسول من 2: 1 إلى 200: 1. يتعلق الاختراع أيضًا بعملية لتحضيرها، استخدامها كدواء، وبالوقاية من و/أو علاج الأمراض الالتهابية inflammatory diseases أو الحالات الالتهابية. شكل1
SA519410841A 2017-06-23 2019-12-18 تركيبة مستحلب نانو زيت في ماء من كلوبيتاسول SA519410841B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382393 2017-06-23
PCT/EP2018/051218 WO2018233878A1 (en) 2017-06-23 2018-01-18 OIL NANOEMULSION COMPOSITION IN CLOBETASOL WATER

Publications (1)

Publication Number Publication Date
SA519410841B1 true SA519410841B1 (ar) 2022-06-05

Family

ID=59285129

Family Applications (1)

Application Number Title Priority Date Filing Date
SA519410841A SA519410841B1 (ar) 2017-06-23 2019-12-18 تركيبة مستحلب نانو زيت في ماء من كلوبيتاسول

Country Status (32)

Country Link
US (1) US10857160B2 (ar)
EP (1) EP3641728B9 (ar)
JP (1) JP7065895B2 (ar)
KR (1) KR102571107B1 (ar)
CN (1) CN110944625B (ar)
AU (1) AU2018288256B2 (ar)
CA (1) CA3067657A1 (ar)
CL (1) CL2019003707A1 (ar)
CO (1) CO2020000026A2 (ar)
CR (1) CR20200024A (ar)
CY (1) CY1124193T1 (ar)
DK (1) DK3641728T3 (ar)
DO (1) DOP2019000307A (ar)
EC (1) ECSP19089679A (ar)
ES (1) ES2875851T3 (ar)
HR (1) HRP20210865T1 (ar)
HU (1) HUE055016T2 (ar)
IL (1) IL271474B (ar)
LT (1) LT3641728T (ar)
MX (1) MX2019015410A (ar)
MY (1) MY190953A (ar)
PE (1) PE20200736A1 (ar)
PH (1) PH12019550291A1 (ar)
PL (1) PL3641728T3 (ar)
PT (1) PT3641728T (ar)
RU (1) RU2759901C2 (ar)
SA (1) SA519410841B1 (ar)
SG (1) SG11201912393XA (ar)
SI (1) SI3641728T1 (ar)
TW (1) TWI768056B (ar)
WO (1) WO2018233878A1 (ar)
ZA (1) ZA202000128B (ar)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024005726A1 (en) * 2022-06-30 2024-01-04 Ilko Ilac Sanayi Ve Ticaret A.S. Storage stable topical composition comprising clobetasol

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA966579B (en) * 1995-08-04 1998-02-02 Wakamoto Pharma Co Ltd O/W emulsion composition for eye drops.
US8449867B2 (en) * 2004-08-31 2013-05-28 Stiefel Research Australia Pty Ltd Microemulsion and sub-micron emulsion process and compositions
EP1796636B2 (en) * 2004-08-31 2016-12-14 Stiefel Research Australia Pty Ltd Microemulsion & sub-micron emulsion process & compositions
FR2889662B1 (fr) * 2005-08-11 2011-01-14 Galderma Res & Dev Emulsion de type huile-dans-eau pour application topique en dermatologie
KR101534422B1 (ko) * 2008-05-14 2015-07-09 오토노미, 인코포레이티드 귀 질환 치료를 위한 제어 방출형 코르티코스테로이드 조성물 및 방법
US20110045050A1 (en) * 2009-08-24 2011-02-24 Atrium Medical Corporation Nanoemulsion formulations for direct delivery
US9789123B2 (en) * 2010-10-21 2017-10-17 Cadila Healthcare Limited Topical pharmaceutical compositions containing nanodroplets for the treatment of psoriasis
MX2013004296A (es) * 2010-10-21 2013-09-26 Cadila Healthcare Ltd Composiciones farmaceuticas topicas que contienen gotas de tamaño nanometrico para el tratamiento de soriasis.
CN102283850B (zh) * 2011-08-25 2013-04-10 西北农林科技大学 一种水包油型复方酮康唑纳米药物及其制备方法
ES2922815T3 (es) * 2015-02-06 2022-09-20 Woodstock Sterile Solutions Inc Preparación de una emulsión de aceite en agua para formulaciones farmacéuticas estabilizadas con polímeros
WO2016141098A1 (en) * 2015-03-05 2016-09-09 Allergan, Inc. Self-emulsifying drug delivery system (sedds) for ophthalmic drug delivery
TWI773641B (zh) * 2015-05-08 2022-08-11 日商活效製藥股份有限公司 含有糖皮質類固醇（ｇｌｕｃｏｃｏｒｔｉｃｏｉｄｓ）之奈米微粒子之水性懸浮液劑
DK3310389T3 (da) * 2015-06-18 2020-08-10 Bausch Health Ireland Ltd Topiske sammensætninger omfattende et kortikosteroid og et retinoid til behandling af psoriasis
WO2017037663A1 (en) * 2015-09-02 2017-03-09 Cadila Healthcare Limited Topical compositions comprising corticosteroids

Also Published As

Publication number Publication date
MX2019015410A (es) 2021-09-30
JP2020524672A (ja) 2020-08-20
CN110944625A (zh) 2020-03-31
HUE055016T2 (hu) 2021-10-28
CR20200024A (es) 2020-03-12
JP7065895B2 (ja) 2022-05-12
EP3641728A1 (en) 2020-04-29
ES2875851T3 (es) 2021-11-11
LT3641728T (lt) 2021-08-10
KR102571107B1 (ko) 2023-08-25
PH12019550291A1 (en) 2021-01-11
RU2019144015A (ru) 2021-07-23
CO2020000026A2 (es) 2020-04-24
KR20200019945A (ko) 2020-02-25
US20190298737A1 (en) 2019-10-03
TWI768056B (zh) 2022-06-21
RU2759901C2 (ru) 2021-11-18
IL271474A (en) 2020-01-30
PE20200736A1 (es) 2020-07-23
CA3067657A1 (en) 2018-12-27
ECSP19089679A (es) 2020-05-29
DK3641728T3 (da) 2021-06-07
ZA202000128B (en) 2021-01-27
CN110944625B (zh) 2022-05-03
IL271474B (en) 2022-09-01
SI3641728T1 (sl) 2021-08-31
SG11201912393XA (en) 2020-01-30
AU2018288256A1 (en) 2020-01-30
DOP2019000307A (es) 2020-03-15
TW201904562A (zh) 2019-02-01
CL2019003707A1 (es) 2020-06-05
CY1124193T1 (el) 2022-05-27
MY190953A (en) 2022-05-24
EP3641728B9 (en) 2021-06-30
PT3641728T (pt) 2021-06-14
RU2019144015A3 (ar) 2021-07-23
WO2018233878A1 (en) 2018-12-27
AU2018288256B2 (en) 2023-09-28
EP3641728B1 (en) 2021-03-10
US10857160B2 (en) 2020-12-08
PL3641728T3 (pl) 2021-09-20
HRP20210865T1 (hr) 2021-08-20

Similar Documents

Publication Publication Date Title
MX2022014313A (es) Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada.
MY156858A (en) Low-oil pharmaceutical emulsion compositions comprising progestogen
EP2271314A4 (en) COMPOSITIONS AND METHODS FOR PREPARING NANOEMULSIONS
MX2016006641A (es) Composición novedosa y método de uso para controlar patógenos y prevenir enfermedades en semillas.
AR104835A1 (es) Composiciones nutricionales que contienen un nivel elevado de inositol y uso de las mismas
EP4233889A3 (en) Activin-actrii antagonists and uses for treating myelodysplastic syndrome
AR075412A1 (es) Composiciones para el aseo personal que comprenden preparaciones especificas de aceites constituidos por trigliceridos saturados hidrogenados, con relacion a aceites insaturados metodo de preparacion
CL2019002513A1 (es) Composiciones de limpieza cosmética.
PE20080658A1 (es) Formulaciones de metilnaltrexona en forma de polvo seco
NZ723838A (en) Cannabinoid compositions and uses
WO2017037593A3 (zh) 用于减少局部脂肪的医药组成物及其用途
WO2018231905A8 (en) Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia
AR079639A1 (es) Composicion de pasta de dientes anti-erosiva
PH12019500970A1 (en) Composition for the treatment and/or prevention of the black sigatoka fungal disease in banana crops
SA519410841B1 (ar) تركيبة مستحلب نانو زيت في ماء من كلوبيتاسول
CO2020005366A2 (es) Composición plaguicida que contiene tidiazurón y ácido poliglutámico
CL2015002832A1 (es) Formulación farmaceutica que comprende fosfatidilcolina para el tratamiento de colitus ulcerosa.
CO2022004529A2 (es) Composición de xantofila que comprende luteína y zeaxantina con biodisponibilidad mejorada
CO2021016029A2 (es) Composición de partículas que contienen cocristal de ácido málico y malato de hidrógeno de metal alcalino
MX2017009098A (es) Manufactura de confiteria congelada.
WO2017152130A8 (en) Pharmaceutical compositions
PE20211198A1 (es) Metodos y formulaciones para tratar nauseas y vomitos inducidos por quimioterapia
WO2019044529A8 (en) Oil-in-water emulsion composition comprising ether oil
AR112236A1 (es) Pesticida
WO2012039768A3 (en) Itraconazole formulations